Skip to content
  1. Home
  2. Latest news
  3. Johnson & Johnson takes a top spot on the 2017 Thomson Reuters Diversity & Inclusion Index
A photo of a woman leading a meeting

Johnson & Johnson takes a top spot on the 2017 Thomson Reuters Diversity & Inclusion Index

The company came in at #2 on the list of the 100 most diverse and inclusive workplaces around the world.

Johnson & Johnson has secured the #2 ranking on the 2017 Thomson Reuters Diversity & Inclusion Index.

The index selects the top 100 publicly traded companies out of a pool of more than 6,000, based on performance across such categories as diversity, inclusion and people development.

Johnson & Johnson’s positioning—up two spots from last year—reinforces its long commitment to creating a “culture of belonging” among its more than 130,000 employees worldwide, according to Chief Diversity & Inclusion Officer Wanda Bryant Hope.

“Johnson & Johnson is proud to be recognized as #2 on the Thomson Reuters Diversity & Inclusion Index,” she says. “We know the best way to reach the patients, doctors and consumers we serve—whose demographics are rapidly changing—is by having a workforce that reflects their diversity. The commitment we have to inclusion is a key element in further enabling our people to be themselves, deliver their best and change the world.”


Why a Diverse Workforce Is a Priority for Us

Johnson & Johnson prides itself on its diversity & inclusion initiatives, which helped us top the Thomson Reuters list.

More from Johnson & Johnson

Terra Kremer, Ph.D., is on a mission to create self-sterilizing surgical tools

Since its launch, Johnson & Johnson has focused on helping make surgeries safer. Learn how this analytical microbiologist and her team are continuing in that tradition with a digital app that aims to change the way medical devices are designed and sterilized.

What is lupus?

Up to 5 million people worldwide live with this complex autoimmune condition, which is more prevalent in women and has a greater disease severity in Latin Americans and patients of African ancestry. Learn how Johnson & Johnson is working to innovate treatments for autoimmune diseases.

This scientist develops targeted treatments for cancer—here’s what drives and inspires him

Learn more about Zhao, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.